GS
RXRX icon

GTS Securities’s Recursion Pharmaceuticals RXRX Stock Holding History

GTS Securities’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-34,174
Closed -$105K – 1790
2026
Q1 		$105K Buy
+34,174
New +$132K ﹤0.01% 1423
2025
Q4 		– Sell
-52,557
Closed -$256K – 1729
2025
Q3 		$256K Buy
+52,557
New +$276K 0.01% 1138
2023
Q4 		– Sell
-10,476
Closed -$80.1K – 4362
2023
Q3 		$80.1K Buy
+10,476
New +$105K ﹤0.01% 3637

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

GTS Securities's RXRX Position: Q2 2026 in Review

GTS Securities sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 34,174 shares — an estimated $105K sold.

GTS Securities first reported a position in RXRX in Q3 2023 and held it in 3 quarters. The position peaked at $256K in Q3 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • GTS Securities reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • GTS Securities sold 34,174 Recursion Pharmaceuticals shares in Q2 2026, an estimated $105K.
  • GTS Securities first reported a position in Recursion Pharmaceuticals in Q3 2023 and held it in 3 quarters.
  • GTS Securities's Recursion Pharmaceuticals position peaked at $256K in Q3 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.